EN 
FR 
Optimize Your Healthcare Impact with Cytel's HTA Solutions
Discover Cytel’s comprehensive health technology assessment (HTA) support. We merge our advanced analytical methods with strategic insights to illuminate your product’s true economic value for informed healthcare policy decision-making.
Cytel's Expertise in Health Technology Assessment
Health Technology Assessment (HTA) is crucial for evaluating the clinical, economic, and ethical impact of new healthcare technologies to guide policy decisions on drug pricing and reimbursement. Cytel supports this critical process with bespoke modeling solutions that reflect the true value of your medical innovations. From global strategies to local execution, we have specialist services to support your reimbursement submissions and survival data analysis and ensure market access in stringent HTA jurisdictions. Our approach combines global insight with local specialist knowledge, aligning with HTA now present on every continent, to help you navigate the complexity of reimbursable market entry.
Contact usReimbursement expertise
We specialize in core model development for successful reimbursement submissions across diverse healthcare systems.
Analytical solutions
Overcome challenges associated with immature survival data to enhance the robustness of your economic evaluations.
Market access proficiency
Secure market access for novel therapies in rigorous HTA contexts, including agencies like NICE, CADTH, and ZIN.
Diverse therapeutic acumen
Broad expertise across therapeutic areas like oncology, immunology, and rare diseases, translating complex data into compelling evidence for HTA submissions.
Our Specialized HTA Services
Cytel stands at the forefront of HTA navigation, providing in-depth expertise to ensure that new therapies are accurately evaluated for efficacy, cost-effectiveness, and budget impact. Our expanded presence, including recent acquisitions, places us among the top full-service market access providers, and our local HTA specialists are ready to tackle first-wave launch markets’ unique challenges. We drive HTA processes by developing evidence generation plans early, ensuring that every HTA submission is strategically crafted for success, from comparative clinical effectiveness to budget optimization.
Navigating 2025's HTA Changes for Seamless EU JCA Transitions
In the evolving landscape of the EU’s healthcare regulation, the advent of Joint Clinical Assessments (JCA) is set to standardize and streamline the assessment process for new health technologies. As a leading partner in this transition, Cytel equips your health technology developers with the tools and expertise to navigate the JCA’s intricacies. By engaging early in evidence generation planning, focusing on pivotal product value identification, synthesis, and demonstration, we ensure you and your team are JCA-ready. Our capabilities in leveraging indirect treatment comparisons, embracing rigorous analytical methodologies, and comprehending local HTA nuances across Europe are critical in achieving favorable outcomes. As the scope of HTA broadens, Cytel’s strategic insight will become essential for developers seeking market access in this harmonized yet complex environment, driving forward both clinical innovation and patient accessibility.
LiveSLR® Suite: Revolutionizing HTA Documentation
The LiveSLR® suite transforms your HTA documentation with agile and precise evidence synthesis tools, integral for establishing your product’s value. As HTA assessments become more complex, Cytel’s LiveSLR® suite simplifies the process, providing a robust framework for systematic literature reviews, adaptable to the evolving landscape of global HTA requirements. This suite ensures that your evidence is not only current and comprehensive but also strategically aligned with the nuanced needs of reimbursement pathways, bolstering your product’s case for market access.
Learn More
Webinar Series on EU-JCA
Watch our recent 2-part webinar series covering EU Joint Clinical Assessment (JCA) and Health Technology Assessment (HTA). The webinars cover the upcoming European HTA regulation, impact on the market, and valuable insights.
Watch Webinar Series
>12
Comparative Effectiveness Statisticians specialized in communicating data to payers and HTA agencies.
>35
Health Economists specializing in HTA submissions.
50
HTA Agencies globally
2025
New EU JCA Process starts January 12, 2025
Related Insights
Early Planning Strategies for External Control Arms in HTA and Regulatory Submissions
Key Elements and Implications of the Draft EU JCA Implementing Act
Unravelling PICO: The Pillars of the European Joint Clinical Assessment
Claim your free 30-minute strategy session
Book a free, no-obligation strategy session with a Cytel expert to get advice on how to improve your drug's probability of success and plot a clearer route to market.